AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01267942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enhancin
Description: Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.~Oral dose of the same at the same dosage for the active comparator arm.
Study NCT01267942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enhancin
Description: Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.~Oral dose of the same at the same dosage for the active comparator arm.
Study NCT03515356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-Walk Intervention
Description: Eight-week motivational enhancement therapy and home-based aerobic walking intervention
Study NCT03515356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Education Pamphlet
Description: Physical activity education pamphlet only
Study NCT03515356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Education Pamphlet
Description: Physical activity education pamphlet only
Study NCT01958983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy Group Session
Study NCT03267888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given 200 mg IV.
Study NCT03267888 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.
Study NCT00417963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting
Description: placement of a bare metal stent at sites of stenosis in the carotid artery
Study NCT00793169 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Serum levels were measured
Study NCT00477646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Care Management
Description: Telephone support over 18 months to help women become screened for breast, cervical and colon cancer. Includes barriers assessment, patient education and motivation, provider recommendation letter, appointment reminder, and some scheduling of appointments.
Study NCT00477152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronidase (human recombinant)/rehydration fluid
Description: Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
Study NCT00005949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT00005949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100:209-217(210M) peptide vaccine
Description: Given SC
Study NCT00005949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01531517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Royal Jelly and Panthenol (PedyPhar® Ointment)
Description: the following will be done to each patient depending on the number of the visit:~1. Assessment of the patient for inclusion/exclusion criteria~2. Informed consent process~3. Medical history of the patient~4. Blood withdrawn for investigation~5. Drainage of the ulcer if there is a collection~6. Revascularization as needed and indicated by APSV done at visit 0.~7. Swab from the ulcer for culture and micro-organism count: on detailed visits only.~8. Debridement as needed.~9. Dressing:~   * Inspection and assessment of the ulcer~  * Irrigation using 500 ml of saline or as required.~  * Drying of the ulcer (leave to dry)~  * Spread a layer of 3 - 5 mm of PedyPhar on a dressing and then apply the dressing to the ulcer~  * Fix the dressing to the ulcer
Study NCT01531517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panthenol Ointment
Description: the following will be done to each patient depending on the number of the visit:~1. Assessment of the patient for inclusion/exclusion criteria~2. Informed consent process~3. Medical history of the patient~4. Blood withdrawn for investigation~5. Drainage of the ulcer if there is a collection~6. Revascularization as needed and indicated by APSV done at visit 0.~7. Swab from the ulcer for culture and micro-organism count: on detailed visits only.~8. Debridement as needed.~9. Dressing:~   * Inspection and assessment of the ulcer~  * Irrigation using 500 ml of saline or as required.~  * Drying of the ulcer (leave to dry)~  * Spread a layer of 3 - 5 mm of Panthenol on a dressing and then apply the dressing to the ulcer~  * Fix the dressing to the ulcer
Study NCT03126435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1
Description: twice weekly
Study NCT03126435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: once weekly
Study NCT03126435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: once weekly
Study NCT01231776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electronic acupuncture
Description: applying a stimula on neiguang and shenmen through electronic acupuncture
Study NCT01231776 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: electronic acupuncture
Description: applying a stimula on neiguang and shenmen through electronic acupuncture
Study NCT01181869 — intervention group
Intervention type: DEVICE
Intervention: oxygen
Description: oxygen therapy, ventilation for respiratory failure CPAP for sleep apnoea
Study NCT00443586 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening plus Transportation
Description: Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
Study NCT00443586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening, Transport, Prenatal Visits
Description: Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
Study NCT03221842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor
Description: C1-esterase inhibitor is a human plasma-derived lyophilised powder for reconstitution
Study NCT03221842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipients of C1-INH plus albumin
Study NCT01286077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
Study NCT00590343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatalanib
Description: Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
Study NCT02156778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Extended Standard Care (Stroke Card)
Description: Standard Care plus~extended training with access to weekly educational lectures (education of patients and relatives), implementation of My Stroke Card containing (a) an adopted version of the 'post-stroke checklist' (ascertainment of post-stroke complications), (b) self-administered internet-based tools for risk factor monitoring and reinforcement of target level achievement, and (c) information and educational materials.~3-Mo outpatient appointment with standardized assessment of risk factors and screening for complications, health problems and residual deficits, estimation of the patient's demand for nursing services and support, guideline-conform secondary prevention with full achievement of target levels, assessment of patient adherence to drug prescriptions.~6-Mo and 9-Mo visits on the discretion of the study team in case of medical needs.~12-Mo clinical visit and outcome assessment.
Study NCT03173157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Value Feedback Email
Description: a biweekly email to three house staff-run cardiology services at VUMC presenting the in-hospital charges and appropriate use of echocardiography. A weekly email will also be sent to the intervention services detailing their team's in-hospital charges for echocardiograms during the preceeding week.
Study NCT00165763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil hydrochloride (Aricept)
Description: 5 mg donepezil HCl given once a day and increased to 10 mg per day if side effects, when present, are tolerated.
Study NCT02156778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Standard Care
Description: In-hospital training (education of patients, next of kin and caregivers on risk factor management and assessment, life style improvement, and compliance).~Complimentary provision of a book / information material dealing with patient and caregiver relevant aspects of stroke care.~Advise by a dietitian (general advise and individualized recommendations in patients with diabetes and obesity).~Standardized information materials (e.g. for OAK or NOAK therapy). Support for smoking cessation and weight reduction if necessary or requested. Detailed medical reports (doctor's letter for the general practitioner and patient) at discharge containing target levels for risk factor management.~AF detection at the Stroke Unit (1-5 day monitoring) and/or at the ward (24-hour ECG).~12-Mo clinical visit and outcome assessment.
Study NCT00443586 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening, Transport, Prenatal Visits
Description: Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
Study NCT00443586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen, Transport, Prenatal/Inf Visits
Description: Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
Study NCT03439969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Text Messages
Description: Dental inter-proximal control with floss holder and receiving 16 SMS during 4 months.
Study NCT04701567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Advanced multiparametric MRI techniques to diagnose hepatic and pancreatic disease
Study NCT03439969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra Oral Camera
Description: SPT - Appointment with Intra-Oral Camera~* Examination and diagnosis (15 min) using Intra-oral camera.~* Motivation, discussion about desired outcomes and treatment needs (using Intra-oral camera) followed by instrumentation (scaling, polishing) (30 min).
Study NCT02276612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food
Study NCT02260284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yaotong points acupuncture
Description: Patients receive the treatments of Yaotong points penetration
Study NCT01737853 — intervention group
Intervention type: DRUG
Intervention: Ganforti
Description: Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
Study NCT01737853 — intervention group
Intervention type: DRUG
Intervention: Krytantek
Description: Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
Study NCT03582891 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Summit RC+S for Motor
Description: Using the RC+S pulse generator, investigators will measure cortical biomarkers of hyper and hypokinesia in Parkinson's and dystonia patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
Study NCT03582891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 8-week pilot trial of Closed-loop vs. Open-loop Stimulation
Description: These patients will participate in an 8 week clinical trial of open loop versus adaptive mode (4 weeks for each mode (interleaved), with the order counterbalanced across subjects ).
Study NCT00191191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2
Description: 500 mg/m2, intravenous (IV), every 21 days, one year from registration date
Study NCT00191191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 1000 mg/m2
Description: 1000 mg/m2, intravenous (IV), every 21 days, one year from registration date
Study NCT00912938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Intravenous zoledronic acid 4mg over a minimum of 15 minutes in at least 100mls of calcium free infusion solution (0.9% sodium chloride or 5% glucose solution) every 4 weeks.
Study NCT02260284 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the usual care
Description: participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS))
Study NCT02260284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized acupuncture
Description: Patients were given to the standardized acupuncture groups. This prescription included six acupuncture points that are commonly applied for the treatment of CLBP (Bladder 23-bilateral, Bladder 40-bilateral, and Kidney 3-bilateral) on the low back and lower leg.
Study NCT04212299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Northwestern University Flexible Sub-Ischial Suction Socket (NU-FlexSIS)
Description: The sub-ischial socket includes a firm, compressive, preferably cylindrical, fabric-covered silicone liner, a flexible inner socket, and a shorter rigid outer socket. The socket has proximal trim lines that do not impinge on the pelvis; they terminate distal to the ischial tuberosity and greater trochanter. For the NU-FlexSIS Socket, passive suction suspension is achieved using a one way valve and a liner with an internal seal.~Since the prosthetic socket is a custom-made device, it is considered Class I exempt by the Food and Drug Administration (FDA).
Study NCT02569294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Description: Hatha-yoga intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by Hatha-yoga trained teachers. This program was developed previously in Montreal and the following were included at each session: 1) preparatory warm-up synchronized with breathing; 2) selected postures (e.g. forward , backward-, and side-bending asanas in sitting and lying positions); 3) deep relaxation; 4) alternate-nostril breathing or pranayama; and 5) meditation. Each participant received a DVD to encourage at-home practice.
Study NCT02569294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention
Description: Hypnosis intervention included 6 sessions of 2 hours every 2 weeks. This was led by an anesthesist with experience in oncology and trained in hypnosis. Based on years of consultation with cancer patients, her team created a negotiating approach that fosters shared decision-making through using tasks that are centered on general well-being rather than on the health problem itself. Patients were asked to be actively involved. Several topics are addressed through tasks: eg. adjusting self-expectations. Patients were also required to keep a work-diary that was reviewed at the beginning of each session. At the end of the session, a 15-min hypnosis exercise is conducted. They receive CDs containing the hypnosis exercises and homework assignments.
Study NCT02569294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT intervention
Description: CBT intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by CBT-trained psychologists with experience in psycho-oncology. This program was developed by team leaders and is modelled on the work of Andersen et al. (2008) and Savard (2010). The intervention targets were: 1) breast cancer, meaning of illness, understanding stress and responses to it; 2) impact of treatment on body image; 3) impact of treatment on self-esteem; 4) fear of recurrence; 5) relationships with relatives and health professionals; and 6) life projects, return to daily activities and work. Relaxation training took place at the end of each session and participants performed tasks between sessions.
Study NCT02765867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: A single injection of RBP-6000 containing a low dose of buprenorphine in the Atrigel delivery system
Study NCT03275467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transfer (FMT)
Description: Suspended stool from a healthy donor
Study NCT04187378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical Underbody Blanket
Description: Surgical blanket is used to maintain normothermia during abdominal surgery
Study NCT04187378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical access blanket
Description: Surgical blanket is used to maintain normothermia during abdominal surgery
Study NCT01371747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 8.4 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
Study NCT01371747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
Study NCT01371747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
Study NCT03582891 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Summit RC+S for Sleep
Description: Using the RC+S pulse generator, investigators will measure cortical biomarkers of sleep stages in Parkinson's patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
Study NCT00434642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was provided as commercially available drug.
Study NCT01371747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
Study NCT00434642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin was provided as commercially available drug.
Study NCT01371747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
Study NCT01371747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 33.6 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
Study NCT01371747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)
Study NCT00434642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was provided as commercially available drug.
Study NCT00434642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was provided as commercially available drug.
Study NCT01371747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)
Study NCT03927456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study NCT01672476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo